Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Newman

Internal Medicine Harvey, LA Medical Doctor

NPI 1316906837 CMS profile 14462

2845 Manhattan Blvd, Harvey, LA 70058

Open in the dashboard

General payments

$5,447

363 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Newman of Harvey, LA is reported in the CMS Open Payments database as having received $5,447 across 363 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,065 60
2024 General $1,023 58
2023 General $881 57
2022 General $363 18
2021 General $14 1
2019 General $2,102 169

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Newman
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to William Newman were reported at $1,065. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year William Newman Internal Medicine median Middle half National median
2019 $2,102 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $14 $135 $37–$521 $132
2022 $363 $141 $42–$496 $149
2023 $881 $149 $45–$519 $160
2024 $1,023 $154 $47–$537 $164
2025 $1,065 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $852 74 payments
  2. AbbVie, Inc. $671 43 payments
  3. GlaxoSmithKline, LLC. $657 47 payments
  4. AstraZeneca Pharmaceuticals LP $586 26 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $562 32 payments
  6. Pfizer Inc. $397 26 payments
  7. Novo Nordisk Inc $258 21 payments
  8. Merck Sharp & Dohme Corporation $240 22 payments
  9. Dexcom, Inc. $192 9 payments
  10. Sanofi-Aventis U.S. LLC $163 12 payments
  11. Other $870 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,433 361 payments
  2. Education $14 2 payments
Products named General payments · program years 2019–2025
  1. MOUNJARO $500 38 payments
  2. TRELEGY ELLIPTA $440 32 payments
  3. JARDIANCE Diabetes $344 35 payments
  4. FARXIGA $342 12 payments
  5. UBRELVY $316 12 payments
  6. TRULICITY $300 30 payments
  7. ZEPBOUND $276 23 payments
  8. AIRSUPRA $262 8 payments
  9. BREZTRI $261 7 payments
  10. JARDIANCE Diabetes $240 11 payments
  11. Other $4,850 356 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 186 drugs

Part D claims

16,069

Median for Pediatric Medicine: 38

Drug cost

$1,127,370

Median for Pediatric Medicine: $2,769

Branded share of claims

18.9%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 170 $196,214
Eliquis Apixaban Brand 127 $143,201
Linzess Linaclotide Brand 116 $107,004
Jardiance Empagliflozin Brand 103 $103,806
Ozempic Semaglutide Brand 47 $97,247
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 51 $37,564
Tresiba Flextouch U-100 Insulin Degludec Brand 52 $29,261
Trulicity Dulaglutide Brand 22 $27,826
Myrbetriq Mirabegron Brand 30 $26,929
Xarelto Rivaroxaban Brand 21 $26,005

The 10 drugs with the highest cost, of 186 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$37,564

Medicare's payments for the services billed

Medicare patients

250

Average age 75

Services billed

898

133 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 49%
Diabetes 24%
Ischemic heart disease 22%
Chronic kidney disease 22%
Depression 21%
Cancer 16%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $102
  • Lilly USA, LLC $33
$135 103 —
LINZESS
  • Ironwood Pharmaceuticals, Inc $64
  • AbbVie, Inc. $59
$123 116 —
MOUNJARO
  • Lilly USA, LLC $113
$113 170 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $65
$65 — —
ZEPBOUND
  • Lilly USA, LLC $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

363 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record